Galectin Therapeutics (GALT) ( (GALT) ) has released its Q2 earnings. Here is a breakdown of the information Galectin Therapeutics (GALT) presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Galectin Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for fibrotic disease and cancer using galectin science. In its latest earnings report for the quarter ended June 30, 2025, the company reported a net loss of $7.5 million, a decrease from the $12.4 million loss in the same period last year. Operating expenses were significantly reduced, with research and development expenses dropping to $3.3 million from $9.8 million a year ago. Despite the reduction in expenses, the company continues to operate at a loss, with no revenue generated. The company’s cash and cash equivalents stood at $13.8 million, down from $15.1 million at the end of 2024. Galectin Therapeutics has secured a new $10 million line of credit to support its operations through June 2026. Looking ahead, the company plans to raise additional capital through various strategic transactions to support its ongoing research and development efforts.